Dark and dramatic sky with sunlight
Biotech

After ‘complete standstill,’ biotech market reaches new normal

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several areas, such as cardiorenal and neuropsych.
Gabrielle Masson Aug 20, 2025 11:04am
Investigational Rosnilimab Emerges as a Novel Differentiated Treatment Option for Rheumatoid Arthritis

Investigational Rosnilimab Emerges as a Novel

Aug 18, 2025 8:00am
space launch rocketship

Rocket’s gene therapy free from FDA hold

Aug 20, 2025 10:40am
Goal disorientation and lack of vision

Celldex ends esophageal program despite hitting primary endpoint

Aug 20, 2025 6:42am
RFK sworn in
Favicon Fierce Healthcare

After shooting, HHS staff call for RFK to stop sowing mistrust

Aug 20, 2025 1:38pm
deal handshake business cooperation partnerships

IQVIA, Veeva go from adversaries to partners

Aug 20, 2025 1:32pm
More News

Iantrek sees $42M fundraising for alternative glaucoma surgery

Aug 20, 2025 11:50am

FDA draft recommends all cancer trials collect OS data

Aug 20, 2025 10:59am

Painted into a corner, Mural agrees to Xoma buyout

Aug 20, 2025 10:28am

Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble

Aug 20, 2025 9:13am